-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: biotechnology investment
Scientific American Worldview Scorecard Correlates with International Investment
Biotechnology innovation requires investment, and the Scientific American Worldview Scorecard can predict where investment goes. A recent analysis indicates that the ranking of countries in this Scorecard correlates with global investment. As a result, the Worldview Scorecard provides a valuable tool for any country interested in increasing its appeal to biotechnology investors. In short, the Worldview Scorecard uses a wide collection of data – compiled and analyzed by Yali Friedman – that generates a metric Read More >
It Takes a Village: The New Pharma-VC Model for Biotech Investing
High-profile funding collaborations between pharmaceutical companies and traditional venture capital funds have made headlines in recent months, pooling resources and expertise in an attempt to source and develop the most successful drugs. BIO Executive Vice President Alan Eisenberg moderated It Takes a Village: The New Pharma-VC Model for Biotech Investing, a panel discussion about these new funding models, during the opening plenary session at the 2012 BIO Investor Forum. In the past, venture capital could Read More >
Finding Value in Early Stage Collaborations at the BIO Technology Transfer Symposium
The BIO Technology Transfer Symposium dissects recent academia-industry collaborations and evaluates the value in early stage biotechnology investments. The event occurs in San Francisco on October 8th ahead of the BIO Investor Forum and provides a unique opportunity for bringing academia, industry, and the investment community together. This year’s event is headlined by Tom Thornton from the Cleveland Clinic, a leading academic medical center. The first panel highlights the collaboration between Duke Translational Research Institute Read More >
Five Keys to Making Biotech Flourish in China
As China positions itself as a major global player in the international biotechnology arena, it has included biotechnology as one of the seven strategic priorities for scientific and technological development in its 12th Five-year Plan. During the keynote lunch of the China Day special program at the 2012 BIO International Convention, David W. Beier, senior vice president at Amgen and former chief domestic policy advisor to Vice President Al Gore, outlined the 5 keys to Read More >
IPO Update – Jan 2012
2011 ended quietly for the US biotech IPO market. It has now been almost two months without a biotech IPO. The last few IPOs back in November continued the theme that was in place at the beginning of the year – you can get out, but with a -30% haircut. In fact, only two of the 12 IPOs in 2011 raised more than they filed for. This is shown in chart 1 below. The two Read More >
